UK leads weight-loss jab searches amid global Mounjaro surge
The worldwide demand for weight-loss injections has skyrocketed, with a recent survey suggesting 24% of Brits would use weight-loss jabs if offered free by the NHS, and an additional 7% are prepared to pay between £180 and £200 monthly.
ZAVA, an online doctor and prescription service, say the United Kingdom has seen the most significant global surge in searches for Mounjaro, with a staggering 4,049.74% increase since January 2024. The monthly search volume skyrocketed from a mere 15,200 in January 2024 to an impressive 630,760 this month.
This dramatic rise in interest aligns with Mounjaro’s approval for obesity treatment in England in November 2023, following its earlier authorisation for type 2 diabetes.
READ MORE: Anas Sarwar's speech marks the new direction Scottish Labour has been waiting for
READ MORE: Scotland's oldest Playboy model who dated Rangers icon is battling 'unbearable' illness
Dr Crystal Wyllie, a doctor at ZAVA, commented on the rising interest in weight-loss injections: "As we enter 2025, the growing interest in weight-loss injections marks a positive shift in how we approach weight management and overall health.
Treatments like Mounjaro offer hope for individuals who have struggled with weight loss through diet and exercise alone, making the process potentially easier and more achievable."
Dr Wyllie also highlights weight-loss treatments do more than just curb appetite - they can contribute to long-term success when paired with a healthy diet and regular exercise.
She states: "They also offer additional health benefits, such as regulating blood sugar and lowering blood pressure, making them valuable for people with conditions like hypertension and type 2 diabetes."
Additionally, the UK also leads global searches for the broader term 'weight loss injections'.
With ZAVA finding the average monthly searches were 102,000, while the searches rose from 49,700 in January 2024 to 194,500 in January 2025.
Join the Daily Record's WhatsApp community here and get the latest news sent straight to your messages.
However, Dr Wyllie emphasises GLP-1 agonist medications are specifically designed for individuals with obesity or those with a BMI of 27 or higher who also have weight-related health conditions.
This means they are not meant for general weight loss but rather for those who need medical intervention to manage their health effectively.